Mereo Halts Plans For US Listing
Mereo BioPharma has withdrawn its Nasdaq public offering, which had a target of raising $80m, because of ‘challenging and volatile’ market conditions in the US.
You may also be interested in...
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
The UK firm, boosted by promising data for acumapimod for acute exacerbations of COPD, is seeking to conduct an initial public offering in the US.
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.